Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer

New England Journal of Medicine

Volumn 380, Issue 8, 2019, Pages 741-751

  Bardia, Aditya ^a   Mayer, Ingrid A ^b   Vahdat, Linda T ^c   Tolaney, Sara M ^a   Isakoff, Steven J ^a   Diamond, Jennifer R ^e   O'Shaughnessy, Joyce ^f   Moroose, Rebecca L ^g   Santin, Alessandro D ^h   Abramson, Vandana G ^b   Shah, Nikita C ^g   Rugo, Hope S ⁱ   Goldenberg, David M ^j   Sweidan, Ala M ^k   Iannone, Robert ^j   Washkowitz, Sarah ^j   Sharkey, Robert M ^j   Wegener, William A ^j   Kalinsky, Kevin ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA HEALTH   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Immunomedics   (United States)

^k AIS Consulting   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; SACITUZUMAB GOVITECAN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELL ADHESION MOLECULE; IRINOTECAN; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ABDOMINAL PAIN; ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE LEVEL; ASTHENIA; BACKACHE; BODY WEIGHT; BODY WEIGHT LOSS; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER THERAPY; CLINICAL EVALUATION; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; URINARY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL ADHESION MOLECULES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; IRINOTECAN; MALE; MIDDLE AGED; NEUTROPENIA; PROGRESSION-FREE SURVIVAL; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85061974711     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1814213     Document Type: Article

References (39)

1. Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am 2013;27: 737-749, viii.
2. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-82.
3. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42.
4. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the National Cancer Database. Medicine (Baltimore) 2016;95(35):e4614.
5. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ ethnicity, poverty, and state. J Natl Cancer Inst 2015;107(6):djv048.
6. Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 2016;10:25-36.
7. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast 2017;31:244-59.
8. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375: 1925-36.
9. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-posi-tive advanced breast cancer. N Engl J Med 2012;367:1783-91.
10. NCCN clinical practice guidelines in oncology: breast cancer, version 1.2018. National Comprehensive Cancer Network, 2018 (https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf).
11. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108-21.
12. Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018;14: 32-9.
13. Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133: 1067-75.
14. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010;121:261-71.
15. Park IH, Im SA, Jung KH, et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with an-thracycline and taxane: PROCEED trial (KCSG BR 11-01). Cancer Res Treat 2019; 51:43-52.
16. Twelves C, Awada A, Cortes J, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin me-sylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl) 2016;10:77-84.
17. Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 2015;21:3870-8.
18. Ripani E, Sacchetti A, Corda D, Al-berti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76:671-6.
19. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013;32:222-33.
20. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res 2005;11:4357-64.
21. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 2015;6:22496-512.
22. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018;9:28989-9006.
23. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:3157-69.
24. Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 2015; 21:5131-8.
25. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 2017;35:2141-8.
26. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
27. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
28. Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinet-ics. Cancer 2017;123:3843-54.
29. Camptosar. New York: Pharmacia & Upjohn, 2016 (package insert).
30. Dean L. Irinotecan therapy and UGT1A1 genotype. In: Pratt V, McLeod H, Rubinstein W, et al., eds. Medical genetics summaries. Bethesda, MD: National Center for Biotechnology Information, April 4, 2018 (https://www.ncbi.nlm.nih.gov/books/NBK294473/).
31. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008;34:656-69.
32. Liu D, Li J, Gao J, Li Y, Yang R, Shen L. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer 2017;17:437.
33. Falvella FS, Cheli S, Martinetti A, et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Phar-macol 2015;80:581-8.
34. Riera P, Salazar J, Virgili AC, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. Br J Clin Pharma-col 2018;84:1389-92.
35. Sharma P. Biology and management of patients with triple-negative breast cancer. Oncologist 2016;21:1050-62.
36. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371:1963-71.
37. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
38. Chuk MK, Chang JT, Theoret MR, et al. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res 2017;23:5666-70.
39. Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol 2018; 4:849-56.